メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
医学部・救急医学・総合内科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(6)
研究成果
(106)
フィンガープリント
医学部・救急医学・総合内科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Systematic Review
100%
Meta-Analysis
88%
Observational Study
45%
Positron Emission Tomography
39%
Emergency Department
31%
Cohort Analysis
31%
Diagnosis
30%
Fever of Unknown Origin
29%
Intensive Care Unit
28%
Cervical Cancer Screening
25%
Fluorine-18
23%
Positron Emission Tomography
22%
Adverse Event
21%
Diagnostic Accuracy
21%
Retrospective Study
20%
Iodinated Contrast Medium
19%
Ganglioglioma
19%
Airway Obstruction
19%
Positron Emission Tomography-Computed Tomography
19%
COVID-19
19%
Intubation
19%
Spontaneous Remission
19%
Acute Kidney Injury
19%
Retrospective Cohort Study
19%
Fluorodeoxyglucose F 18
17%
Pathogen
15%
Infection
13%
Symptom
13%
Omicron Coronavirus Variant
13%
Fluorodeoxyglucose
12%
Cross Sectional Study
12%
Diabetic Ketoacidosis
12%
Assisted Ventilation
11%
Nuclear Imaging
11%
Biological Marker
11%
Heart Arrest
11%
Intensive Care
11%
Computer Assisted Tomography
10%
Streptococcus Pneumoniae
10%
Tertiary Care
10%
High Risk Population
9%
Gallium Citrate Ga 67
9%
Informed Consent
9%
Protamine
9%
Septic Shock
9%
Noradrenalin
9%
Favipiravir
9%
Capillary Leak Syndrome
9%
Community-Acquired Pneumonia
9%
Vein Blood Flow
9%
Clinical Feature
9%
Procedural Sedation and Analgesia
9%
Diffuse Lewy Body Disease
9%
Carotid Atherosclerosis
9%
Cardiac Troponin
9%
Stomach Cancer
9%
Gram-Negative Bacteria
9%
High Dose Chemotherapy
9%
Infective Endocarditis
9%
Helicobacter Pylori
9%
Sputum
9%
Blood Culture
9%
Clinical Management
9%
Induced Hypothermia
9%
Post-Hoc Analysis
9%
Nefiracetam
9%
Choline Acetyltransferase
9%
Asthma
9%
Peripherally Inserted Central Catheter
9%
Sofosbuvir
9%
Hyponatremia
9%
Desmopressin
9%
Network Meta-Analysis
9%
Injection Site Reaction
9%
Reverse Transcription Loop Mediated Isothermal Amplification
9%
Pepsinogen
9%
Intralipid
9%
Risk Communication
9%
Bleeding
9%
Severe Acute Respiratory Syndrome Coronavirus 2
9%
Malignant Neoplasm
9%
Intravenous Drug Administration
9%
Muscarinic Acetylcholine Receptor
9%
Limb Fracture
9%
Scoring System
9%
Myocardial Infarction
9%
Umbrella Review
9%
Pulmonary Pathology
9%
Wart Virus
9%
Low Carbohydrate Diet
9%
Ketoacidosis
9%
Nuclear Magnetic Resonance
9%
Sepsis
9%
Amiodarone
9%
Gram Staining
9%
Hyperosmolarity
9%
Magnetic Resonance Imaging
9%
Mixed Infection
9%
Venous Thromboembolism
9%
Doppler Ultrasonography
9%
Keyphrases
Hyperosmolar Hyperglycemic State
19%
Cyclic Derivative
11%
GABA Derivatives
11%
Japan
11%
Hyperglycemic Crisis
11%
Isolated Perfused Rat Heart
10%
Intrarenal Venous Flow
9%
Favipiravir
9%
Cytochrome P450 2D6 (CYP2D6)
9%
Gallium Nitride
9%
Medium Substitution
9%
Etomoxir
9%
Intrarenal Venous Flow Pattern
9%
Heart Function
9%
Capillary Leak Syndrome
9%
Amnesia
9%
Vasodilatation
9%
Griess Method
9%
Procedural Sedation
9%
Procedural Analgesia
9%
Hospital Cluster
9%
Admission Screening
9%
Home Visits
9%
Pathogen Diagnosis
9%
Spontaneous Remission
9%
Emergency Department
9%
Infective Endocarditis
9%
Injection Site Reaction
9%
Post-occlusive Reactive Hyperemia
9%
Radiation Emergency
9%
Muscarinic Receptors
9%
Sodium Overload
9%
Gram-negative Bacilli Bacteremia
9%
Cervical Cytology
9%
Medical Preparedness
9%
Radiation Disaster
9%
Markov Decision Analysis
9%
Reduced Toxicity
9%
BCR-ABL mutations
9%
Recurrent Glioma
9%
Relapsed CLL
9%
Multiple Treatments Meta-analysis
9%
Refractory CLL
9%
Glioma Diagnosis
9%
SARS-CoV-2 Pneumonia
9%
Ceramide
9%
Peripherally Inserted Central Catheter
9%
Level of Agreement
9%
Patient Disposition
9%
MRNA-1273
9%
Cefcapene pivoxil
9%
Emergency Medicine
9%
SARS-CoV-2 Infection
9%
Amiodarone
9%
Refractory Septic Shock
9%
Medical Prevention
9%
Retrospective Longitudinal Study
9%
Sample Testing
9%
Systematic Review Protocol
9%
7-day Mortality
9%
High-sensitivity Cardiac Troponin
9%
Intralipid
9%
Healthcare-associated COVID-19
9%
Serial Testing
9%
Diacylglycerol
9%
Simultaneous Quantitation
9%
Management Decisions
9%
Flame Ionization Detection
9%
Ischemic Preconditioning
9%
Extremity Fractures
9%
GABAA Receptor (GABAAR)
9%
MIBG Scintigraphy
9%
Review Protocol
9%
Older Surgical Patients
9%
Nuclear Imaging
9%
Cycloheximide
9%
Comparative Accuracy
9%
Vaccination
9%
Screening Decisions
9%
Bayesian Latent Class Model
9%
Umbrella Review
9%
Decision Aid
9%
Response Predictors
9%
Severe Bradycardia
9%
Abnormal Eating Behavior
9%
Fluid Creep
9%
Intravenous Fluid Therapy
9%
Ketoacidosis
9%
Sofosbuvir
9%
Comparative Effectiveness Reviews
9%
Cancer Imaging
9%
Ca2+ Pump
9%
Omicron Wave
9%
Return to Work Program
9%
Mechanical Signals
9%
Oral Glucose
9%
Ethics Statements
9%
Women with Breast Cancer
9%
Retrospective Observational Study
9%
Bacteremia
9%
Pharmacology, Toxicology and Pharmaceutical Science
Cohort Study
32%
Diabetic Ketoacidosis
22%
Observational Study
21%
Iodinated Contrast Medium
19%
Diacylglycerol
19%
Fluorine 18
19%
Cycloheximide
19%
Fluorodeoxyglucose F 18
19%
Remission
19%
Bacteremia
19%
Pyrexia Idiopathica
19%
Inflammation
19%
Disease
16%
Infection
13%
Fatty Acid
13%
Coronavirinae
12%
Hyperglycemia
12%
Receptor
11%
4 Aminobutyric Acid
11%
Retrospective Study
11%
Fluorodeoxyglucose
10%
Helicobacter Pylori
10%
Asthma
9%
Hypothermia
9%
Heart Arrest
9%
Protamine
9%
Nitrite
9%
Favipiravir
9%
Etomoxir
9%
Troponin
9%
Mongrel Dog
9%
Heart Infarction
9%
Takotsubo Cardiomyopathy
9%
High Dose Chemotherapy
9%
Bacterial Endocarditis
9%
Remdesivir
9%
Hyperaemia
9%
Choline Acetyltransferase
9%
Immunotherapy
9%
Stomach Cancer
9%
Hyponatremia
9%
Desmopressin
9%
Syndrome
9%
Cefcapene Pivoxil
9%
Stomach Carcinoma
9%
Allergic Reaction
9%
Adverse Outcome
9%
Low Density Lipoprotein
9%
Pepsinogen
9%
Immunoglobulin G Antibody
9%
Amiodarone
9%
Muscarinic Receptor
9%
Randomized Controlled Trial
9%
Helicobacter
9%
Intralipid
9%
Antiplatelet
9%
Antithrombocytic Agent
9%
Symptom
9%
Limb Fracture
9%
Gram Negative Bacterium
9%
Hyperosmolarity
9%
Diffuse Lewy Body Disease
9%
Snakebite
9%
Ceramide
9%
Nefiracetam
9%
Vaccination Policy
9%
Sofosbuvir
9%
SARS Coronavirus
9%
Vaccine
9%
Acute Kidney Failure
9%
Life Expectancy
6%
Hodgkin Disease
6%
Ischemia
6%
C Reactive Protein
5%